Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.42 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.42 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.41 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.41 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL347578 | 0.86 | LMNA (0.50) | POLBLMNAMEN1KMT2AKDM4E | |
| SCHEMBL17831137 | 0.84 | POLB (0.44) | POLBLMNAMEN1KMT2AKDM4E | |
| SCHEMBL4639714 | 0.84 | POLB (0.53) | POLBLMNAMEN1KMT2AKDM4E | |
| SCHEMBL30577290 | 0.84 | LMNA (0.43) | POLBLMNAMEN1KMT2AKDM4E | |
| SCHEMBL28401117 | 0.83 | KDM4E (0.60) | POLBLMNAMEN1KMT2AKDM4E | |
| SCHEMBL3631470 | 0.83 | KDM4E (0.46) | POLBLMNAMEN1KMT2AKDM4E | |
| SCHEMBL28957162 | 0.82 | KDM4E (0.41) | POLBLMNAMEN1KMT2AKDM4E | |
| SCHEMBL1397262 | 0.82 | POLB (0.50) | POLBLMNAMAPTPRSS1PRSS2 | |
| SCHEMBL7530230 | 0.82 | CYP3A4 (0.56) | POLBLMNAMEN1KMT2AKDM4E | |
| SCHEMBL4924102 | 0.80 | KDM4E (0.42) | POLBLMNAMEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 155 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1773768-B1 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2018-08-22 | — | — | EP | claimed |
| EP-2417125-B1 | N-ARYL-2-(2-ARYLAMINOPYRIMIDIN-4-YL)PYRROL-4-CARBOXAMIDE DERIVATIVES AS MPS1 KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2015-09-09 | — | — | EP | claimed |
| US-8772280-B2 | N-aryl-2-(2-arylaminopyrimidin-4-yl)pyrrol-4-carboxamide derivatives as MPS1 kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-07-08 | — | — | US | claimed |
| EP-2417125-A1 | N-ARYL-2-(2-ARYLAMINOPYRIMIDIN-4-YL)PYRROL-4-CARBOXAMIDE DERIVATIVES AS MPS1 KINASE INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2012-02-15 | — | — | EP | claimed |
| WO-2010108921-A1 | N-ARYL-2-(2-ARYLAMINOPYRIMIDIN-4-YL)PYRROL-4-CARBOXAMIDE DERIVATIVES AS MPS1 KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-09-30 | — | — | WO | claimed |
| EP-1451160-B1 | PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN | ICAGEN INC (US) | 2010-01-13 | — | — | EP | claimed |
| EP-1610779-B1 | 3-OXO-1,3-DIHYDRO-INDAZOLE-2-CARBOXYLIC ACID AMIDE DERIVATIVES AS PHOSPHOLIPASE INHIBITORS | LILLY CO ELI (US) | 2009-09-09 | — | — | EP | claimed |
| EP-1773768-A4 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS INC (US) | 2008-08-06 | — | — | EP | claimed |
| EP-1773768-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | Exelixis, Inc. (US) | 2007-04-18 | — | — | EP | claimed |
| WO-2006012642-A2 | PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS, INC. (US) | 2006-02-02 | — | — | WO | claimed |
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-06-10 | — | — | US | claimed |
| WO-2004018461-A2 | ANTIBACTERIAL BENZOIC ACID DERIVATIVES | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-03-04 | — | — | WO | claimed |
| WO-2004018428-A1 | ANTIBACTERIAL BENZOIC ACID DERIVATIVES | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-03-04 | — | — | WO | claimed |
| WO-2004018414-A2 | ANTIBACTERIAL AGENTS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-03-04 | — | — | WO | claimed |
| WO-2004000806-A1 | AMIDES OF CYCLIC AMINO ACIDS USED AS PDE 4 INHIBITORS | ELBION AG (DE) | 2003-12-31 | — | — | WO | claimed |
| JP-2003528802-A | — | — | 2003-09-30 | — | — | JP | claimed |
| US-20020025977-A1 | N-phenyl benzimidazolecarboxamide and N-phenyl indolecarboxamide derivatives | NEUROGEN CORPORATION | 2002-02-28 | — | — | US | claimed |
| EP-1165517-A1 | N-BENZIMIDAZOLYLMETHYL- AND N-INDOLYLMETHYL-BENZAMIDES AND THEIR USE AS CRF MODULATORS | NEUROGEN CORPORATION (US) | 2002-01-02 | — | — | EP | claimed |
| US-6281237-B1 | MODULATORS OF CRF RECEPTORS AND ARE THEREFORE USEFUL FOR TREATING AFFECTIVE DISORDERS, ANXIETY, DEPRESSION, EATING DISORDERS, AND STRESS DISORDERS | NEUROGEN CORPORATION | 2001-08-28 | — | — | US | claimed |
| WO-2000059888-A1 | N-BENZIMIDAZOLYLMETHYL- AND N-INDOLYLMETHYL-BENZAMIDES AND THEIR USE AS CRF MODULATORS | NEUROGEN CORPORATION (US) | 2000-10-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020025977-A1 | N-phenyl benzimidazolecarboxamide and N-phenyl indolecarboxamide derivatives | CRHR1, CRHR2, HTR2C | POLB 4486/4885LMNA 1333/4885MEN1 3967/4885 |
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | GABRD, GABBR1, GABRA1 | POLB 637/4885LMNA 3376/4885MEN1 4132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.